Sponsor or institution

Clinical trials and research at Intergroupe Francophone de Cancerologie Thoracique

• 7Clinical trials
• 1Country

Newest trials

All recruiting trials (7)

• Fianlimab plus cemiplimab with chemotherapy for unresectable pleural mesothelioma

  This study tests a combo of two immune therapies with chemotherapy to see if it helps people with newly diagnosed, unresectable pleural mesothelioma.

  Recruiting at 9 sites Phase 2 Intergroupe Francophone de Cancerologie Thoracique · Aix-en-Provence and 36 other locations · NCT07234058

• Tarlatamab versus standard chemotherapy for pre-treated advanced pulmonary (large-cell) or gastroenteropancreatic poorly differentiated neuroendocrine carcinomas

  This trial tests whether tarlatamab helps adults with DLL3-positive, pre-treated advanced pulmonary (large-cell) or gastroenteropancreatic poorly differentiated neuroendocrine carcinomas compared with standard chemotherapy.

  Recruiting at 40 sites Phase 3 Intergroupe Francophone de Cancerologie Thoracique · Angers and 39 other locations · NCT06937905

• Tepotinib versus standard treatments for advanced MET exon 14–mutated non-small cell lung cancer after prior therapy

  This study will test whether tepotinib works better than standard chemotherapy choices for people with advanced non-small cell lung cancer that has a MET exon 14 mutation and whose disease progressed after at least one prior treatment.

  Recruiting at 29 sites Phase 3 Intergroupe Francophone de Cancerologie Thoracique · Besançon and 28 other locations · NCT06908993

• Ivonescimab for pleural mesothelioma that returned after immunotherapy and chemotherapy

  This will try ivonescimab, a bispecific antibody targeting VEGF and PD‑1, as a second- or third-line treatment for people with pleural mesothelioma whose cancer progressed after immunotherapy and standard chemotherapy.

  Recruiting at 20 sites Phase 2 Intergroupe Francophone de Cancerologie Thoracique · Besançon and 20 other locations · NCT06840834

• Adjuvant chemotherapy with optional cemiplimab plus short-course sequential radiotherapy for unfit or elderly patients with stage III non-small cell lung cancer

  This tests whether adding the immunotherapy cemiplimab to carboplatin‑paclitaxel chemotherapy and sequential short-course radiotherapy helps unfit or elderly people with unresectable stage III non-small cell lung cancer.

  Recruiting at 25 sites Phase 2 Intergroupe Francophone de Cancerologie Thoracique · Angers and 24 other locations · NCT06656598

• Evaluating molecular factors and resistance mechanisms in lung cancer treatment

  This study is testing how well a specific lung cancer treatment works for patients with certain gene mutations and aims to find out why some patients might not respond to the treatment or have a relapse.

  Recruiting at 36 sites Intergroupe Francophone de Cancerologie Thoracique · Angers and 35 other locations · NCT06053099

• Shortening immunotherapy duration for advanced lung cancer patients

  This study is testing if advanced lung cancer patients can safely shorten their immunotherapy treatment from two years to six months while still keeping their cancer under control.

  Recruiting at 2 sites Phase 2/3 Intergroupe Francophone de Cancerologie Thoracique · Aix-en-Provence and 43 other locations · NCT05255302

Quick answers

How many clinical trials run by Intergroupe Francophone de Cancerologie Thoracique are recruiting right now?

7, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

All of them have sites in France. Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 2: 3, Phase 3: 2, Phase 2/3: 1. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →